Phase II evaluation of chlorozotocin in patients with non-small cell carcinoma of the lung

E. S. Casper, R. J. Gralla

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

Because of the reported activity of the lipid-soluble nitrosoureas in non-small cell carcinoma of the lung, a phase II trial of chlorozotocin in this disease was undertaken. Thirty-five patients were enlisted in the study between March 1977 and March 1978. Two PRs were noted in the 30 (7%) evaluable patients. At 95% confidence limits, the predicted true response rate is 2%-18%. The authors conclude that chlorozotocin, when given in the present dose and schedule, is only a marginally effective agent in the treatment of non-small cell carcinoma of the lung, and that it offers no therapeutic advantage over the nitrosoureas currently used in the treatment of this disease.

Original languageEnglish (US)
Pages (from-to)549-550
Number of pages2
JournalCancer Treatment Reports
Volume63
Issue number4
StatePublished - Dec 1 1979

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II evaluation of chlorozotocin in patients with non-small cell carcinoma of the lung'. Together they form a unique fingerprint.

  • Cite this